1. Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, Magenis RE, Moncla A, Schinzel AA, Summers JA, Wagstaff J. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet. 2006;140A:413–8.
https://doi.org/10.1002/ajmg.a.31074
.
2. Dagli A, Buiting K, Williams CA. Molecular and Clinical Aspects of Angelman Syndrome. Mol Syndromol. 2012;2(3–5):100–12.
3. Clayton-Smith J, Laan LA. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet. 2003;40(2):87–95.
4. Food and Drug Administration (FDA); US Department of Health and Human Services; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER); Center for Devices and Radiological Health (CDRH). Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
21-01-18. Accessed 21 Jan 2018.
5. Lowe MM, Blaser DA, Cone L, Arcona S, Ko J, Sasane R, Wicks P. Increasing patient involvement in drug development. Value in Health. 2016;19(6):869–78.